Sisram Medical Ltd (HKG:1696)
Hong Kong · Delayed Price · Currency is HKD 5.76
-0.36 (-5.88%)
Aug 1, 2025, 4:08 PM HKT
Sisram Medical Revenue
In the year 2024, Sisram Medical had annual revenue of $349.11M USD, down -2.83%. Sisram Medical had revenue of $180.38M in the half year ending December 31, 2024, with 0.23% growth.
Revenue
$349.11M
Revenue Growth
-2.83%
P/S Ratio
0.99
Revenue / Employee
$343.95K
Employees
1,015
Market Cap
2.70B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 349.11M | -10.18M | -2.83% |
| Dec 31, 2023 | 359.29M | 4.81M | 1.36% |
| Dec 31, 2022 | 354.48M | 60.19M | 20.45% |
| Dec 31, 2021 | 294.29M | 132.20M | 81.56% |
| Dec 31, 2020 | 162.10M | -11.43M | -6.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
Sisram Medical News
- 11 months ago - Sirsram Medical announces NMPA approval for DAXXIFY® - Benzinga